Nasdaq · Healthcare
Burning Rock Biotech Ltd (BNR)
As-reported financials and recent SEC filings for Burning Rock Biotech Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$539.6M
Net income
$-55.3M
Net margin
-10.3%
Diluted EPS
—
ROE
-10.3%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $539.6M | $515.8M | $537.4M | $563.2M | $507.9M |
| Gross profit | $402.9M | $362.4M | $363.2M | $380.0M | $364.1M |
| Operating income | $-54.8M | $-357.6M | $-669.3M | $-980.4M | $-797.1M |
| Net income | $-55.3M | $-346.6M | $-653.7M | $-971.2M | $-796.7M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →6-K2026-06-09
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →SCHEDULE 13G/A2026-05-13
View on EDGAR →20-F2026-04-28
View on EDGAR →42026-04-02
View on EDGAR →32026-03-18
View on EDGAR →32026-03-17
View on EDGAR →Largest Healthcare peers
Go deeper on BNR
Search Burning Rock Biotech Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.